| US 7,579,371 B2 | ||
| Methods of using [3.2.0] heterocyclic compounds and analogs thereof | ||
| Michael Palladino, Olivenhain, Calif. (US); Barbara Christine Potts, Escondido, Calif. (US); Venkata Rami Reddy Macherla, San Diego, Calif. (US); and Saskia Theodora Cornelia Neuteboom, La Jolla, Calif. (US) | ||
| Assigned to Nereus Pharmaceuticals, Inc., San Diego, Calif. (US) | ||
| Filed on Jun. 15, 2006, as Appl. No. 11/453,374. | ||
| Application 11/453374 is a continuation in part of application No. 11/412476, filed on Apr. 27, 2006. | ||
| Application 11/412476 is a continuation in part of application No. 11/118260, filed on Apr. 29, 2005, granted, now 7,276,530. | ||
| Claims priority of provisional application 60/567336, filed on Apr. 30, 2004. | ||
| Claims priority of provisional application 60/580838, filed on Jun. 18, 2004. | ||
| Claims priority of provisional application 60/591190, filed on Jul. 26, 2004. | ||
| Claims priority of provisional application 60/627462, filed on Nov. 12, 2004. | ||
| Claims priority of provisional application 60/644132, filed on Jan. 13, 2005. | ||
| Claims priority of provisional application 60/659385, filed on Mar. 04, 2005. | ||
| Claims priority of provisional application 60/676533, filed on Apr. 29, 2005. | ||
| Prior Publication US 2007/0004676 A1, Jan. 04, 2007 | ||
| Int. Cl. A61K 31/407 (2006.01); A61K 31/343 (2006.01) | ||
| U.S. Cl. 514—421 [514/469] | 31 Claims |
1. A method of treating cancer comprising administering to an animal a compound having the structure of Formula VI-A, or a
pharmaceutically acceptable salt or pro-drug ester thereof:
 wherein R1 is selected from the group consisting of a mono-substituted, poly-substituted or unsubstituted variants of the following residues:
saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl, unsaturated C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl,
arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, phenyl, cycloalkylacyl, alkylthio, arylthio,
oxysulfonyl, carboxy, thio, sulfoxide, sulfone, boronic acid, boronic ester, and halogenated alkyl including polyhalogenated
alkyl;
wherein p is equal to 1 or 2;
wherein R2, is selected from the group consisting of hydrogen, a halogen, mono-substituted, poly-substituted or unsubstituted variants
of the following residues: saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl, unsaturated C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl,
arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy,
alkylthio, arylthio, oxysulfonyl, carboxy, cyano, thio, sulfoxide, sulfone, sulfonate ester, thiocyano, boronic acid, boronic
ester, and halogenated alkyl including polyhalogenated alkyl;
wherein R3 is selected from the group consisting of a halogen, mono-substituted, poly-substituted or unsubstituted variants of the following
residues: saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl, unsaturated C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl,
arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy,
alkylthio, arylthio, oxysulfonyl, carboxy, cyano, thio, sulfoxide, sulfone, sulfonate ester, thiocyano, boronic acid, boronic
ester, and halogenated alkyl including polyhalogenated alkyl;
wherein R14 is selected from the group consisting of a halogen, mono-substituted, poly-substituted or unsubstituted variants of the following
residues: saturated C1-C24alkyl, unsaturated C2-C24 alkenyl, unsaturated C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl,
arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy,
alkylthio, heteroalkylthio, arylthio, oxysulfonyl, carboxy, cyano, thio, thioesters, sulfoxide, sulfone, sulfonate ester,
thiocyano, and halogenated alkyl including polyhalogenated alkyl;
wherein each of E1 and E3 is a substituted or unsubstituted heteroatom selected from the group consisting of O and S, E2 is a substituted or unsubstituted N or —CH2—, and E4 is a substituted or unsubstituted heteroatom selected from the group consisting of O, S, and N; and
wherein the cancer is selected from the group consisting of breast cancer, sarcoma, leukemia, uretal cancer, bladder cancer,
colon cancer, rectal cancer, stomach cancer, lung cancer, lymphoma, liver cancer, kidney cancer, endocrine cancer, skin cancer,
melanoma, angioma, and brain or central nervous system (CNS) cancer.
|